HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silvestre, J.-S. Articles by Delcayre, C. Search for Related Content PubMed PubMed Citation Articles by Silvestre, J.-S. Articles by Delcayre, C. Social Bookmarking                      What's this?

J Biol Chem, Vol. 273, Issue 9, 4883-4891, February 27, 1998

Myocardial Production of Aldosterone and Corticosterone in the Rat
PHYSIOLOGICAL REGULATION^*

Jean-Sébastien Silvestre, Valérie Robert, Christophe Heymes, Brigitte Aupetit-Faisant^§, Christian Mouas, Jean-Marie Moalic, Bernard Swynghedauw, and Claude Delcayre^¶

From INSERM U127, Hôpital Lariboisière, 75475 Paris Cedex 10, France

	ABSTRACT

Top Abstract Introduction Procedures Results Discussion References

Increasing evidence suggests that mineralo- and glucocorticoids modulate cardiovascular homeostasis via the effects of circulating components generated within the adrenals but also through local synthesis. The aim of this study was to assess the existence of such a steroidogenic system in heart.

Using the quantitative reverse transcriptase-polymerase chain reaction, the terminal enzymes of corticosterone and aldosterone synthesis (11-hydroxylase and aldosterone synthase, respectively) were detected in the rat heart. This pathway was shown to be physiologically active, since production of aldosterone, corticosterone, and their precursor, deoxycorticosterone, was detected in both the homogenate and perfusate of isolated rat hearts using radioimmunoassay after Celite column chromatography. Perfusion of angiotensin II or adrenocorticotropin for 3 h increased aldosterone and corticosterone production and decreased deoxycorticosterone, suggesting that aldosterone and corticosterone are formed within the isolated heart from a locally present substrate.

Chronic regulation of this intracardiac system was then examined. As in adrenals cardiac 11-hydroxylase and aldosterone-synthase mRNAs were independently regulated by 1 week's treatment with either low sodium and high potassium diet (which increased aldosterone synthase mRNA level only), angiotensin II (which raised level of both mRNAs), or adrenocorticotropin (which stimulated the 11-hydroxylase gene exclusively). Changes in cardiac steroid levels during treatment were not directly related to their plasma levels suggesting independent regulating mechanisms. This study, therefore, provides the first evidence for the existence of an endocrine cardiac steroidogenic system in rat heart and emphasizes its potential physiological and pathological relevance.

	INTRODUCTION

Top Abstract Introduction Procedures Results Discussion References

Glucocorticoids (corticosterone in the rat and cortisol in humans) and mineralocorticoids (mainly aldosterone in both species) are synthesized from cholesterol, predominantly in the adrenal cortex. The two forms of the cytochrome P-450 enzyme which catalyze the final step of these synthetic pathways are encoded by two closely related genes CYP11B1 and CYP11B2, respectively (1) but display differences in their enzymatic activity, regulation, and tissular distribution (2). P-450 11-hydroxylase (11-OHase)¹ synthesizes corticosterone from 11-deoxycorticosterone (DOC) in the zona fasciculata reticularis and is mainly regulated by adrenocorticotropic hormone (ACTH). P-450 aldosterone (Aldo)-synthase, which catalyzes synthesis of aldosterone from DOC, is present only in the zona glomerulosa. Its activity is principally controlled by angiotensin II (Ang II) and potassium and more weakly by ACTH and sodium (3, 4). While ACTH is a chronic inhibitor of aldosterone secretion, it is also a potent stimulator of its synthesis in some acute conditions (5, 6). Two other P-450c11 genes, CYP11B3 and CYP11B4 were recently cloned from a rat genomic library (7). CYP11B3 was 97% identical to CYP11B1 and encoded an enzyme with activities intermediate between those of 11-OHase and Aldo-synthase (8), whereas CYP11B4 appeared to be a pseudogene (7).

Besides this classical adrenal biosynthetic pathway, extra-adrenal sites of steroid hormone production have been identified (9), for example in brain (10) and more recently in vessels. Indeed, aldosterone and corticosterone production and 11-OHase and Aldo-synthase gene expression have been demonstrated in mesenteric rat artery and in endothelial and smooth muscle cells isolated from human pulmonary artery (11-13). Moreover, Hatakeyama et al. (13) showed that this vascular aldosterone potentiates Ang II-induced hypertrophy of cultured vascular smooth muscle cells, suggesting a physiological role for this locally generated steroid. To date, there is no information regarding aldosterone or corticosterone synthesis within the heart. However, Knox and Lockett (14) have previously demonstrated that isolated hearts produce a substance whose physicochemical properties are consistent with those of aldosterone. The detection of 3-hydroxysteroid dehydrogenase activity (which produces progesterone from pregnenolone) in rat heart also indicates the potential for steroid metabolism in cardiac tissue (15).

Several lines of evidence indicate that glucocorticoids and aldosterone may influence cardiac function. (i) Glucocorticoid and mineralocorticoid receptors have been identified in human and rodent heart (16-18); (ii) 11-hydroxysteroid dehydrogenase, which converts glucocorticoids to their inactive 11-keto metabolites and confers mineralocorticoid specificity to aldosterone target tissues (19), has also been detected in cardiac cells (20); (iii) aldosterone triggers cardiac fibrosis (21, 22) and electrolyte imbalance (23, 24); and (iv) glucocorticoids regulate the cardiac expression of a subset of steroid-responsive genes (25, 26). We hypothesize that mineralocorticoids and glucocorticoids modulate cardiac homeostasis not only via the effects of circulating components generated within the adrenal glands, but also through local synthesis. The aim of this study was, therefore, to assess the existence of such a local system in the rat heart.

To test this hypothesis, we investigated 11-OHase and Aldo-synthase gene expression in rat heart by a quantitative polymerase chain reaction after reverse transcription. We then measured basal aldosterone and corticosterone production in the isolated rat heart using Celite column chromatography coupled with radioimmunoassay. Finally, we examined the regulation of this cardiac endocrine system using 1 week of treatment with a low sodium/high potassium diet, Ang II, or ACTH. This study provides direct evidence that local pathways of aldosterone and corticosterone synthesis exist in rat heart. Furthermore, this cardiac steroid production is regulated by the classical stimuli of adrenal steroid biosynthesis.

	EXPERIMENTAL PROCEDURES

Top Abstract Introduction Procedures Results Discussion References

Animals

The study, which was conducted in accordance with both institutional guidelines and those formulated by the European community for the use of experimental animals (L358-86/609/EEC), was performed using 2-month-old male Wistar rats (Iffa Credo, Lyon, France). For chronic experiments (protocol 2 below), animals were randomly divided into four groups, each group receiving one of the following treatments: (i) a low sodium and high potassium group (0.01% Na⁺ and 2% K⁺ in chow); (ii) Ang II (100 ng/kg/min) infused via a subcutaneous osmotic minipump (Alzet 2002, Charles River, Paris, France); (iii) ACTH (5 ng/kg/min) infused by osmotic minipump; and (iv) a sham-operated group, with an osmotic minipump containing only physiological serum. Systolic blood pressure was measured by the tail-cuff method. After 1 week of treatment, rats were anesthetized by intraperitoneal injection of sodium pentobarbital (60 mg/kg), and blood was collected for measurements of aldosterone, corticosterone, and deoxycorticosterone concentration and renin activity.

Cardiac Perfusion

Hearts were excised and immediately dropped into ice-cold Krebs-Henseleit buffer. After cessation of beating, hearts were rapidly mounted on an aortic cannula, and retrograde perfusion was initiated as described previously (27). Briefly, hearts were perfused with modified Krebs-Henseleit solution (pH 7.4, 37 °C) containing (in mM) NaCl 120, KCl 5, NaHCO₃ 25, MgSO₄ 1.2, KH₂PO₄ 1.2, CaCl₂ 1.2, glucose 11, sodium pyruvate 5, and bovine serum albumin 0.15% (fraction V, Pentex, Miles), oxygenated with a 95% O₂, 5% CO₂ gas mixture. Contractile parameters, oxygen consumption, and coronary flow were continuously recorded until cardiac perfusion was completed.

Experimental Protocol 1-- In this set of experiments, hearts from control rats were perfused for 3 h under different conditions. To wash out plasma components from the heart and allow equilibration, hearts were perfused during the first 15 min at a pressure of 60 mm Hg without recycling of the buffer. They were then perfused for 3 h with 100 ml of recirculating buffer containing either Ang II (10⁸ M) or ACTH (10⁸ M) (Sigma, St. Quentin Fallavier, France). Thus, time 0 of perfusion indicates the onset of Ang II or ACTH perfusion. 10-ml samples of cardiac perfusate were collected at times 0, 1, 2, and 3 h, and steroid concentrations were corrected for volume variation due to sample removal.

At times 0 or 3 h, perfusion was stopped, and the heart was homogenized in 2 volumes of methanol using an Ultra-Turrax apparatus and centrifuged for 15 min at 3000 × g. The recovered supernatant was used for steroid assays. 3000 cpm of each tritiated steroid were added before homogenization to assess steroid loss. Recovery from tissue was 80-90%, and results were corrected accordingly. The protein concentration of cardiac homogenate was determined according to the method of Bradford (28), with bovine serum albumin used as a standard.

Many of the effects of Ang II and ACTH have well characterized dose-response curves. To assess a putative dose-related effects of Ang II and ACTH on cardiac steroid production, hearts were perfused with increasing peptide concentrations (10¹⁰, 10⁹, 10⁸, and 10⁷ M) for 3 h, as described above.

Experimental Protocol 2-- Hearts excised from rats treated for 1 week with a low Na⁺/high K⁺ diet, Ang II, or ACTH were perfused without recycling the buffer. After the initial wash out and equilibration (15 min), 10 ml of perfusate were collected, perfusion was stopped, and hearts were homogenized as described above.

Hormone Assay

Steroids were extracted from the collected perfusates using chloroform. Extracted perfusate and cardiac homogenate were dried under vacuum and redissolved in a 0.25 M phosphate buffer (pH 7) containing sodium azide (2 g/liter) with 3000 cpm of each tritiated steroid to calculate recovery. Steroids were separated in a column composed of Celite and silica gel (Celite 545, Silica Gel 60, Fluka, Paris, France) using a polarity gradient of isoacetane and ethyl acetate. Recovery ranged from 40 to 60%, and results were corrected for this. Levels of aldosterone, corticosterone, and deoxycorticosterone were determined in duplicate by radioimmunoassay using rabbit polyclonal antibodies. The cross-reactivity of each specified antibodies with different biological steroids has been previously described (29). Radioimmunoassay was performed in a 0.25 M phosphate buffer (pH 7), containing sodium azide (2 g/liter) and gelatin (1 g/liter). The accuracy of each series of assays was determined by the addition of various known amounts of unlabeled steroid. To verify that the hormones released into perfusate were not degraded in Krebs buffer, exogenous steroids were added during perfusion.

Incubation of Cardiac Homogenate with 11-[³H]Deoxycorticosterone

To confirm that immunoassays measured bona fide steroids and did not cross-react with other steroidal compounds, cardiac homogenate was incubated with [³H]DOC. Briefly, hearts from control rats were perfused with or without Ang II (10⁸ M) as described in experimental protocol 1. After 3 h, perfusion was stopped, and the heart was minced with scissors and washed twice in physiological serum. The heart was then homogenized using a chilled glass homogenizer in ice-cold buffer (pH 7.4) containing 0.25 M sucrose, 15 mM malate, 5 mM MgCl₂, 10 mM EGTA, 10 mM Tris-HCl, 10 mM KH₂PO₄, 0.075% bovine serum albumin (fraction V, Pentex, Miles), and protease inhibitors (1 mM phenylmethysulfonyl fluoride, 1 µM pepstatin, 1 µM leupeptin, and 0.1 µM aprotinin). Insoluble matter was removed by centrifugation. The supernatant was then incubated aerobically for 1 h at 37 °C in 2 ml of buffer (composition as above) containing 90 pmol of deoxy-[1,2-³H]corticosterone (specific activity, 47 Ci/mmol; Amersham Corp., Les Ulis, France), as described previously (30). Steroids were then extracted by chloroform and separated as described under "Hormone Assay." Unlabeled steroids were added with chloroform to assess steroid loss. The radioactivity of the corresponding fraction was counted using a scintillation counter. Aliquots of each fraction were used for radioimmunoassay to assay unlabeled steroids and to calculate recovery. The protein concentration was determined according to the method of Bradford (28), with bovine serum albumin used as a standard.

Total RNA Extraction

Each heart was separated into its four constituent chambers. Total RNA was extracted from these cardiac tissues and the adrenal glands according to Trizol reagent protocol (Life Technologies, Inc., Cergy Pontoise, France). The yields of total RNA extracted were similar in all four cardiac chambers, in control and treated hearts, and in nonperfused and perfused hearts. The quality of RNA was confirmed by ethidium bromide staining in 1% agarose gel.

Quantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)

Primers-- Oligonucleotide primers (Bioprobe Systems, Montreuil, France) were chosen in homologous parts of the coding region of 11-OHase and Aldo-synthase genes (Fig. 1, panel A). The sense primer was 5'-ACTCCGTGGCCTGAGACG-3' (position 363-381 bp, exon II) and the antisense primer 5'-CTGTGTGGTGGACTTGAA-3' (position 709-691 bp, exon IV) according to the sequence published by Nomura et al. (1). We obtained a PCR product of 346 bp for each transcript after RT-PCR amplification (Fig. 2A, left panel).

View larger version (26K): [in this window] [in a new window]   Fig. 1.   Panel A, schematic organization of the rat 11-hydroxylase and Aldo-synthase genes. Top, schematic organization of the gene with the location of exons shown by boxes and introns by horizontal lines. The exons are numbered from the 5' end of the gene, with exon 1 containing the first codon, ATG. Bottom, the mRNA with the limits of exons, the positions of the primers () and the XhoI site (). Panel B, schematic organization of the rat CYP11B3 gene. Top, schematic organization of the gene; middle, the mRNA with the limits of exons; bottom, specific oligonucleotide primers used for RT-PCR amplification and comparison with 11-hydroxylase nucleotide sequences. The dashes refer to the bases that are identical in the two sequences.

View larger version (72K): [in this window] [in a new window]   Fig. 2.   Panel A, RT-PCR analysis of cardiac 11-hydroxylase and Aldo-synthase mRNA levels in the four cardiac chambers of adult rat heart. 400 and 800 ng of total RNA with 1500 molecules of internal standard were assayed for 32 cycles. Amplified products were electrophoresed onto a 5% polyacrylamide gel. After RT-PCR amplification, we obtained a PCR product of 346 bp for each transcript (left panel). The two PCR products are then size-differentiated using XhoI, which hydrolyzed the Aldo-synthase PCR product into two fragments of 177 and 169 bp (right panel). Panel B, 11-hydroxylase and Aldo-synthase mRNA densities in the four cardiac chambers of adult rat heart. Values are mean ± S.E., n = 6 per group. *p < 0.05 atria versus ventricles. Abbreviations: MW, molecular weight standards IX (Boehringer Mannheim); Stand, internal standard; 11H, 11-hydroxylase; AS, Aldo-synthase; RA, right atrium; LA, left atrium; RV, right ventricle; and LV, left ventricle.

The CYP11B3-specific sense primer was 5'-CGTCGGATGACGCTGGAGT-3' (position 322-340 bp, exon II), and the antisense primer was 5'-AGTGTCCTTTCCACACCT-3' (position 768-749 bp, exon IV) (Fig. 1, panel B) according to the sequence published by Mukai et al. (7). CYP11B3-specific primers are compared with the 11-OHase nucleotide sequence in Fig. 1, panel B. We obtained a PCR product of 445 bp after RT-PCR amplification (see Fig. 3), as described previously (8).

Internal Standard Preparation-- To quantify transcripts of 11-OHase and Aldo-synthase enzymes by RT-PCR, target mRNA was coamplified with a defined concentration of specific internal standard (cRNA). The PCR product was subcloned into a pSP(64) poly(A) vector (Promega, Charbonnières, France). Sequence analysis of the subcloned cDNA (Euro Séquences Gènes Services, Montigny le Bretonneux, France) confirmed 100% identity with the published sequence of 11-OHase (1). Since the cardiac 11-OHase mRNA level was 7-fold higher than that of Aldo-synthase, we subcloned 11-OHase cDNA. The 11-OHase PCR product was then linearized with NcoI and ligated with a 100-bp insert (PvuI/ScaI fragment of pBluescript II SK phagemid). The internal standard was obtained using SP6 RNA polymerase after template linearization with PstI, and the transcription reaction was performed using labeled UTP as a precursor. Transcript concentration was determined after measurement of the radioactivity incorporated into the RNA product. After RT-PCR, we obtained a PCR product of 446 bp (Fig. 2A, left panel).

Quantitative RT-PCR Protocol-- Total RNA was incubated with a fixed amount of internal standard and 200 units of Moloney murine leukemia virus RT (Life Technologies, Cergy pontoise, France) in a 20-µl reaction volume containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl₂, 10 mM dithiothreitol, 0.1 µg/ml bovine serum albumin, 1 mM dNTP, 0.2 µM oligo-p(dT)₁₅ primer (Boehringer Mannheim, Meylan, France), and 50 units of RNase inhibitor (Promega, Charbonnières, France). This reaction mixture was incubated for 10 min at 25 °C, then for 75 min at 40 °C, and the reaction was stopped by heating for 3 min at 94 °C. The resultant single strand cDNA was amplified using 0.5 µM of each sense and antisense primer and 2.5 units of Taq DNA polymerase (Boehringer Mannheim, Meylan, France) in 50 µl of 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 3.75 mM MgCl₂, 1 mM dNTP, and 0.01% gelatin. 32 and 30 amplification cycles were undertaken for heart and adrenals, respectively, as follows: denaturation at 94 °C for 1 min, annealing of primers at 61 °C for 1 min, and primer extension at 72 °C for 1 min. A trace of [-P³²]dCTP was included in the PCR reaction for quantification of the different products. The number of C residues present in each fragment (11-OHase = 69, Aldo-synthase = 74, and internal standard = 95) was taken into account for this quantification. CYP11B3 mRNA amplification was carried out using the same protocole but annealing of the CYP11B3 primer was performed at 59 °C for 32 cycles.

Differentiation by Enzymatic Digestion of 11-OHase and Aldo-Synthase PCR Products-- After RT-PCR amplification, we obtained a PCR product of 346 bp for each transcript as expected (Fig. 2A, left panel). The two PCR products were then size-differentiated using XhoI, which hydrolyzed the Aldo-synthase PCR product into two fragments of 177 and 169 bp. XhoI did not affect the PCR products of 11-OHase or the internal standard (Figs. 1, panel A, and 2A, right panel). Digestion efficiency was verified in preliminary experiments using other restriction enzymes (TaqI, MaeII) and the hydrolyzed 11-OHase PCR product (PstI, PvuII).

PCR products were separated on a 5% polyacrylamide gel, and radioactive signals were analyzed using a computer-based imaging system (Bas 1000, Fuji Medical Systems, Clichy, France).

Validity of the RT-PCR Method-- (Data not shown.) Cardiac mRNA concentrations were determined after 32 cycles, i.e. within the exponential amplification phase of both cardiac mRNA and standard RNA sequences. Indeed, a linear increase in the number of log amplified target molecules was observed between 28 and 33 PCR cycles. The amplification efficiency was the same (93%) for 11-OHase, Aldo-synthase, and their specific internal standard as demonstrated by their parallel amplification curves. The absence of competition between endogenous and synthetic RNA was indicated by the linear relationship between the amount of radioactivity incorporated into the PCR products and the initial amount of RNA. In contrast, the radioactivity incorporated into the internal standard of each tube remained unchanged. These PCR tests were also performed for adrenal tissue RNA.

Statistical Analysis

Statistical significance was estimated between two groups using one-way analysis of variance and group-to-group comparison using Student's t test. Tests were considered significant when p < 0.05. All values presented are the mean ± S.E.

	RESULTS

Top Abstract Introduction Procedures Results Discussion References

11-OHase and Aldo-Synthase mRNA Levels and Steroid Production in Normal Hearts

Cardiac Gene Expression-- 11-OHase and Aldo-synthase mRNA levels were higher in atria than in ventricles (1.5- and 1.3-fold for the 11-OHase mRNA level and 1.3- and 1.4-fold for the Aldo-synthase mRNA level in right and left atria versus right and left ventricles, respectively). 11-OHase mRNA levels were 7-fold higher than those of Aldo-synthase in each cardiac cavity (Fig. 2, A and B). CYP11B3 gene expression was undetectable in the heart of 2-month-old rats (Fig. 3). In contrast, a low level of CYP11B3 mRNA was observed in the heart of 21-day-old rats. We also observed a similar developmental regulation in the adrenal glands, consistent with previous reports (8).

View larger version (54K): [in this window] [in a new window]   Fig. 3.   RT-PCR analysis of CYP11B3 mRNA levels in heart and adrenals of 21-day- and 2-month-old rats. 500 and 1000 ng of total RNA were assayed for 32 cycles. Amplified products are electrophoresed onto a 5% polyacrylamide gel. Abbreviations: MW, molecular weight standards VIII (Boehringer Mannheim); 21d, 21-day-old rats; 60d, 2-month-old rats.

Cardiac Steroid Production-- Hearts of control rats were perfused for 15 min with Krebs buffer to wash out plasma steroids before measurement. They were then perfused for 3 h with Krebs buffer, in the presence or absence of Ang II or ACTH, according to protocol 1 as described under "Experimental Procedures."

Homogenate-- Aldosterone, corticosterone, and DOC were detected in the homogenate of isolated rat heart, until completion of perfusion, under baseline conditions (Fig. 4). Basal cardiac levels of these steroids were modified by Ang II and ACTH. Indeed, Ang II and ACTH enhanced aldosterone production by 3.5- and 3.4-fold, respectively and corticosterone production by 2- and 3-fold, respectively (Fig. 4, A and B). In contrast, DOC levels (Fig. 4C) fell 1.7- and 1.6-fold in response to 3 h of Ang II and ACTH perfusion, respectively.

View larger version (30K): [in this window] [in a new window]   Fig. 4.   Production of aldosterone (panel A), corticosterone (panel B), and deoxycorticosterone (panel C) in the homogenate of isolated perfused rat heart under baseline conditions (white bars) and after 3 h of Ang II (108 M, (light gray bars), or ACTH (108 M, (dark gray bars) perfusion. At the end of perfusion, hearts were homogenized in methanol. Steroids were assayed in cardiac homogenate using radioimmunoassay after Celite column chromatography. Ang II indicates angiotensin II and ACTH, adrenocorticotropic hormone. Values are mean ± S.E., n = 6 per group. *p < 0.05, **p < 0.01, ***p < 0.001 versus control.

Perfusate-- Aldosterone, corticosterone, and DOC were all detected in the perfusate of isolated rat heart, until completion of perfusion, under baseline conditions (Fig. 5). Again, Ang II infusion produced a rise in levels of both aldosterone (8-fold) and corticosterone (1.4-fold). ACTH induced a rapid rise in aldosterone levels (4.9-fold, after 1 h of perfusion) (Fig. 5A) and a slower rise in corticosterone levels (1.5-fold, after 2 h of perfusion) (Fig. 5B). In contrast, DOC levels fell rapidly, 0.7-fold at 1 h, and were undetectable after 2 h in response to either Ang II or ACTH perfusion (Fig. 5C).

View larger version (18K): [in this window] [in a new window]   Fig. 5.   Time course of aldosterone (panel A), corticosterone (panel B), and deoxycorticosterone (panel C) production in the coronary sinus effluent (perfusate) of isolated perfused rat hearts under baseline conditions () and during 3 h of Ang II (108 M, ) or ACTH (108 M, ) perfusion. Steroids are extracted from cardiac perfusate with chloroform and assayed using radioimmunoassay after Celite column chromatography. Values are mean ± S.E., n = 6 per group. *p < 0.05, **p < 0.01, ***p < 0.001 versus baseline.

Dose-response Curves-- The effects of increasing concentrations of Ang II and ACTH on cardiac steroid production are showed in Fig. 6. Levels of both aldosterone and corticosterone in cardiac homogenate rose from 1.8- to 4.6-fold and 1.6- to 3.9-fold, respectively, in response to increasing Ang II concentrations from 10⁹ to 10⁷ M during 3 h of perfusion. In contrast, DOC levels fell from 1.4-fold (10⁹ M) to 5-fold (10⁷ M) in a dose-dependent fashion. ACTH also raised aldosterone and corticosterone levels at a concentration of 10⁹ M (2.3- and 1.6-fold, respectively) and 10⁸ M (3.7- and 3-fold, respectively). In contrast, ACTH led to a dose-dependent 1.4-fold (10¹⁰ M) to 2.7-fold (10⁸ M) decrease in DOC levels. ACTH effects on cardiac steroid production seemed maximal at 10⁸ M. An ACTH and Ang II dose-related effect was also obtained in cardiac perfusate (data not shown).

View larger version (18K): [in this window] [in a new window]   Fig. 6.   Dose-response curves for aldosterone (panel A), corticosterone (panel B), and deoxycorticosterone (panel C) production in the homogenate of isolated perfused rat heart after 3 h of Ang II (0 to 107 M, ) or ACTH (0 to 107 M, ) perfusion. Ang II indicates angiotensin II and ACTH adrenocorticotropic hormone. Values are mean ± S.E., n = 5 per group. *p < 0.05, **p < 0.01, versus baseline conditions (i.e. perfusion without Ang II or ACTH).

Conversion of [³H]DOC to [³H]Corticosterone and [³H]Aldosterone in Cardiac Homogenate-- In control heart, 18 and 5% of [³H]DOC was converted to [³H]corticosterone and [³H]aldosterone, respectively (58.93 ± 4.54 and 15.36 ± 1.14 pmol/mg of protein/h for corticosterone and aldosterone, respectively). Ang II increased the conversion of [³H]DOC to [³H]corticosterone and [³H]aldosterone by 1.9-fold (111.88 ± 27.82 and 29.55 ± 3.10 pmol/mg of protein/h for corticosterone and aldosterone, respectively; both p < 0.01 versus control values).

Effects of Chronic Treatment with Low Na⁺/High K⁺ Diet, Ang II, or ACTH

Rats were treated for 1 week with a low Na⁺/high K⁺ diet, Ang II, or ACTH. At the time of sacrifice, hearts were excised and perfused according to protocol 2.

Anatomical and Physiological Data-- Systolic blood pressure increased after 1 week of Ang II (58%) and ACTH (17%) treatment (Table I). Ang II-treated rats developed moderate left ventricular hypertrophy (23% increase in left ventricular weight/right ventricular weight ratio).

View this table: [in this window] [in a new window]   Table I Effects of chronic treatment with low Na+/high K+ diet, Ang II, or ACTH on anatomical and physiological parameters Rats were treated for 1 week.

Plasma Hormones in Control and Treated Rats-- Plasma aldosterone levels (Table II) were increased by a low Na⁺/high K⁺ diet (3.5-fold) and treatment with Ang II (4.2-fold), but reduced by ACTH (0.8-fold). Plasma corticosterone concentrations were increased by all three treatments (1.9-, 3.6-, and 2.3-fold for low Na⁺/high K⁺, Ang II, and ACTH, respectively). Treatments with Ang II and ACTH raised plasma levels of DOC (4.2- and 2.3-fold, respectively). Plasma renin activity was affected only by a low Na⁺/high K⁺ diet, which caused a significant increase (37%).

View this table: [in this window] [in a new window]   Table II Effects of chronic treatment with low Na+/high K+ diet, Ang II, or ACTH on plasma concentrations of aldosterone, corticosterone and deoxycorticosterone At time of sacrifice, after 1 week of treatment, blood was collected for plasma assay of aldosterone, corticosterone, deoxycorticosterone concentrations and renin activity.

11-OHase and Aldo-Synthase mRNA Levels in Treated Hearts-- Figs. 7 and 8 (A and B) illustrate the changes in left ventricle 11-OHase and Aldo-synthase mRNA levels in response to a low Na⁺/high K⁺ diet, Ang II, or ACTH. A low Na⁺/high K⁺ diet increased Aldo-synthase mRNA levels by 2-fold, whereas 11-OHase mRNA levels remained unchanged. Ang II increased the concentrations of 11-OHase and Aldo-synthase mRNA 4- and 3.4-fold, respectively. ACTH raised the 11-OHase mRNA level 3.2-fold but had no effect on Aldo-synthase mRNA. Similar regulations were found in the right ventricle (Fig. 8, C and D).

View larger version (69K): [in this window] [in a new window]   Fig. 7.   RT-PCR of cardiac 11-hydroxylase and Aldo-synthase mRNA levels in the left ventricle of adult rats treated for 1 week with either a low Na+/high K+ diet, Ang II, or ACTH. 200 and 400 ng of total RNA with 1500 molecules of internal standard were assayed for 32 cycles. RT-PCR products were loaded onto a 5% polyacrylamide gel before (panel A) and after (panel B) XhoI digestion. Abbreviations: MW, molecular weight standards VIII (Boehringer Mannheim); Stand, internal standard; 11H, 11-hydroxylase; AS, Aldo-synthase.

View larger version (46K): [in this window] [in a new window]   Fig. 8.   Effects of treatment for 1 week with either a low Na+/high K+ diet, Ang II, or ACTH on 11-hydroxylase (panels A, C, and E) and Aldo-synthase (panels B, D, and F) mRNA concentrations in the left ventricle (A and B), right ventricle (C and D), and adrenal glands (E and F). Values are mean ± S.E., n = 6 per group. *p < 0.05, **p < 0.01, and ***p < 0.001 versus sham-operated rats.

Cardiac Steroid Production in Treated Hearts-- Hearts from rats treated for 1 week with a low Na⁺/high K⁺ diet, Ang II, or ACTH were perfused for 15 min to wash out plasma steroids. Concentrations of aldosterone, corticosterone, and DOC were then measured in the homogenate and perfusate (Table III). A low Na⁺/high K⁺ diet raised levels of aldosterone by 3.8- and 11.3-fold and corticosterone by 3.7- and 1.7-fold in both homogenate and perfusate, respectively. Ang II treatment increased concentrations of aldosterone (4.4- and 16.7-fold), corticosterone (2.9- and 2.5-fold), and DOC (3.6- and 4.9-fold) in both homogenate and perfusate, respectively. Interestingly, ACTH enhanced aldosterone production 4.5-fold in the homogenate and 15-fold in the perfusate, but decreased plasma aldosterone levels (0.8-fold) (see Table II).

View this table: [in this window] [in a new window]   Table III Effects of chronic treatment with low Na+/high K+ diet, Ang II, or ACTH on cardiac production of aldosterone, corticosterone, and deoxycorticosterone in the homogenate and in the perfusate of isolated perfused rat heart At the end of 1 week of treatment, hearts were excised and perfused 15 min with Krebs-Henseleit buffer to rule out steroids derived from plasma. Cardiac steroids were then assayed in the homogenate and in the perfusate of isolated perfused rat heart as described in experimental procedures.

11-OHase and Aldo-Synthase mRNA Levels in Control and Treated Adrenal Glands-- As in the heart, basal adrenal concentration of 11-OHase mRNA was 7.4-fold higher than that of Aldo-synthase mRNA (Fig. 8, E and F). Similar regulatory changes were observed in the adrenals as in left and right ventricles. A low Na⁺/high K⁺ diet increased Aldo-synthase mRNA levels only (4.2-fold). Treatment with Ang II raised the concentrations of both 11-OHase and Aldo-synthase mRNA 2- and 8.5-fold, respectively, whereas treatment with ACTH stimulated 11-OHase gene expression exclusively (3.9-fold), as described previously (4, 31, 32).

	DISCUSSION

Top Abstract Introduction Procedures Results Discussion References

The main results of this study are: (i) 11-OHase and Aldo-synthase, but not CYP11B3, genes are expressed in the heart of the 2-month-old rat; (ii) cardiac tissue produces the steroid hormones, aldosterone, corticosterone, and DOC; (iii) this myocardial system is regulated by the same stimuli as the adrenals (sodium, potassium, Ang II, and ACTH); and (iiii) cardiac and plasma steroid concentrations seem independently regulated.

Evidence for a Cardiac System of Steroid Synthesis-- In this study, we demonstrate cardiac expression of genes encoding key enzymes involved in the biosynthesis of adrenal gluco- and mineralocorticoids. Cardiac concentration of 11-OHase and Aldo-synthase mRNAs was approximately 1000-fold lower in the heart than in the adrenals. However, the total amount of both mRNA molecules in the whole heart was only 100-fold lower than in the adrenal glands. Such a ratio is comparable with that of angiotensin-converting enzyme mRNA, whose total quantity is about 150-fold lower in heart than in the lungs, one of the main sources for this enzyme (33). We could not detect CYP11B3 mRNA (the third P-450c11 gene) in the hearts of 2-month-old rats. However, CYP11B3 was expressed in cardiac tissue 21 days after birth. Thus, cardiac CYP11B3 gene expression is developmentally regulated, as previously described in the adrenal glands (8).

Cardiac levels of 11-OHase mRNA were 7-fold higher than those of Aldo-synthase mRNA. Interestingly, we also found a similar ratio in adrenals consistent with previous reports (34). Extra-adrenal expression of these genes has already been demonstrated in brain (10) and blood vessels (11, 13). In contrast to cardiac muscle and adrenals, Aldo-synthase gene expression in vascular cells is higher than that of 11-OHase (35), suggesting that the cardiac steroid biosynthetic pathway is similar to that of the adrenal glands but different from that of blood vessels.

The present study demonstrates for the first time that major adrenocortical hormones, i.e. aldosterone, corticosterone, and DOC, are synthesized within the heart. To quantify the cardiac steroid concentration and to avoid contamination by plasma steroids, measurements were performed in an isolated rat heart preparation. Steroid concentrations were determined using immunoassays in both cardiac homogenate (representing the quantity of intracellular hormones) and in cardiac perfusate (representing the quantity of steroids released into the coronary circulation). The cardiac homogenate is able to convert [³H]DOC to [³H]aldosterone and [³H]corticosterone, thus increasing our confidence that the immunoassays measured the correct steroids and did not cross-react with other steroidal compounds.

The estimated molarity of aldosterone in myocardium is about 16 nM, a value 17-fold higher than the mean plasma value (0.93 nM). Several explanations for this cardiac concentration effect are possible. For instance, aldosterone degradation may be slower in cardiac tissue than in plasma, or may be segregated intracellularly once produced and/or locally delivered into the extracellular space instead of being released into plasma. In support of the latter hypothesis, aldosterone was almost undetectable in perfusate under base-line conditions. Furthermore, the concentration of aldosterone in the adrenal glands is about 130 mM, i.e. 140 times greater than the plasma concentration. Similar results have been reported for Ang II by Danser et al. (36), who found local Ang II concentrations 5-10 times higher in cardiac extracellular fluid than in plasma. Extremely high Ang I and Ang II levels (100-fold higher than in plasma) have also been measured in the interstitial fluid compartment of the dog heart (37). This in situ synthesis of a biologically active hormone may thus result in a far greater concentration within tissue that could be achieved via the bloodstream, supporting a putative physiological role. It is noteworthy that the situation was different for glucocorticoids; the concentration we found in plasma (205 nM) was close to that in the homogenate (143 nM).

The basal level of cardiac steroids (i.e. after wash out and before stimulation) presumably derives in part from the circulating pool and in part from endogenous synthesis. It is, however, important to note that variations from this value in the perfused heart preparation can be secondary to cardiac metabolism only. Addition of Ang II and ACTH to the perfusing buffer had two effects which provide conclusive evidence that steroids were produced in the heart: (i) aldosterone and corticosterone levels increased in both cardiac homogenate and perfusate, and (ii) the level of DOC (the precursor of both steroids) decreased simultaneously. Taken together, these experiments indicate that the biochemical components of a steroid biosynthetic pathway, i.e. 11-OHase and Aldo-synthase, are present within rat heart and that this pathway is functional.

This study reinforces the concept that endogenous systems are present in cardiac tissue and that these systems exert autocrine and paracrine influences on local tissue function, as initially suggested by the demonstration of atrial natriuretic factor production by myocytes (38). The existence of an intrinsic cardiac renin angiotensin system and myocardial production of angiotensin I and II have also been described (25, 39). It has been postulated that such a system may be involved in chronic regulation of cardiovascular function (39). Recently, Huang et al. (40) have identified adrenergic cells in rodent and human heart, which constitutively release norepinephrine and epinephrine and thereby affect the spontaneous beating rate of cultured neonatal rat cardiomyocytes.

Regulation of Cardiac Steroid Synthesis-- To assess the putative physiological role of this cardiac steroidogenic system, we investigated its regulation in response to chronic changes in sodium and potassium diet, Ang II, or ACTH, all of which control steroid biosynthesis in the adrenal glands (2).

Seven days of low Na⁺/high K⁺ diet resulted in increased concentrations of aldosterone and corticosterone in the heart associated with a rise in the level of Aldo-synthase mRNA but not 11-OHase mRNA. These results suggest that a low Na⁺/high K⁺ diet increases cardiac aldosterone synthesis in the adrenal glands (32, 41), acting at the transcriptional or post-transcriptional level. In contrast, the rise in corticosterone production induced by the diet suggests a regulation at pretranslational level. These functional differences in gene regulation may reflect structural differences in the 5'-flanking sequences of both P-450 enzymes gene promoters (7, 42).

Ang II is an important regulator of adrenal mineralocorticoid biosynthesis and secretion (4, 43), and it increases the levels of both 11-OHase and Aldo-synthase mRNA in glomerulosa cells (31). The present study shows that the biosynthesis of aldosterone and corticosterone was also under the control of Ang II in cardiac muscle. Moreover, the levels of 11-OHase and Aldo-synthase mRNA in the hearts of Ang II-treated rats were increased by the same order of magnitude as the respective hormones, suggesting transcriptional or post-transcriptional control of their biosynthesis, as in adrenals. Interestingly, DOC levels were increased in the cardiac homogenate and perfusate after 1 week's treatment with Ang II, indicating that precursors of DOC (and thus the entire steroid biosynthetic pathway) may exist in the heart and may be stimulated by such treatment. In contrast, during short term treatment, only the late pathway (i.e. conversion of DOC to aldosterone) was activated, since cardiac DOC levels fell after 3 h of perfusion with Ang II.

ACTH is the most potent stimulator of adrenal steroid synthesis (44). However, stimulation of aldosterone secretion is transitory because chronic treatment with ACTH decreased aldosterone synthesis in adrenals (5, 6). In the present study, ACTH induced a rise in cardiac corticosterone, acting at a transcriptional or post-transcriptional level, but did not affect Aldo-synthase gene expression. Similar regulations have been previously described in cultured vascular or glomerulosa cells (31, 35). In contrast, ACTH induced different effects on aldosterone production in the heart and adrenals; cardiac aldosterone production increased 4.5-fold, whereas plasma levels were decreased slightly (0.8-fold). Several hypotheses could explain this discrepancy. (i) Regulation of steroidogenesis may be tissue-specific, and ACTH acts at a pretranslational level in the heart; (ii) the marked stimulation of the earlier steps of the cardiac biosynthetic pathway (indicated by the increase in corticosterone and DOC) was sufficient to overcome the lack of activation of Aldo-synthase gene transcription; and (iii) the kinetics of aldosterone regulation by ACTH may differ between the heart and adrenal glands. Indeed, ACTH acts on adrenal aldosterone synthesis in two phases, an initial rapid phase of activation and a second one of inhibition. Thus, after 1 week of treatment, aldosterone synthesis was still active in the heart but inhibited in the adrenals.

In summary, a low Na⁺/high K⁺ diet and Ang II induced similar responses in the heart and adrenals. However, changes in cardiac tissue levels of aldosterone and corticosterone during treatment were not directly related to their plasma levels, suggesting independent regulating mechanisms. This hypothesis is supported by the differences between ACTH-induced regulation in the heart and adrenal glands.

Possible Role for Cardiac Aldosterone and Corticosterone Productions-- The detection of glucocorticoid and mineralocorticoid receptors in the heart (16, 17), as well as 11-hydroxysteroid dehydrogenase activity (20), strongly support the possibility of specific actions of aldosterone and corticosterone in the rat heart. The discovery of a local steroidogenic system that responds on both short and long term physiological stimuli suggests paracrine or autocrine actions for these cardiac-generated steroids. Furthermore, the higher aldosterone concentration in heart than in plasma supports also a putative physiological role.

The cardiac effects of mineralo- and corticosteroid hormones remain to be elucidated. Several results from the literature furnish, however, clues for possible cardiac functions. Steroid hormones may be involved in the control of ionic movements since they increase intracellular Ca²⁺ in vascular smooth muscle cells with potential implications for the regulation of vascular tone (45, 46). Aldosterone has also been shown to increase gene expression of major isoforms of Na⁺,K⁺-ATPase in isolated cardiac myocytes (24) and to modulate acid-base balance in cultured neonatal rat cardiac cells via effects on activity of Na⁺/H⁺ and Cl/HCO₃ exchange (47).

Cardiac production of aldosterone and corticosterone was increased by Ang II. Interaction between the renin angiotensin and cardiac steroidogenic systems seems likely since dexamethasone increased Ang II synthesis in the isolated heart (25) and cardiac AT-1 receptor mRNA in vivo (26). Furthermore, aldosterone increases AT-1 receptor density (48) and potentiates Ang II-stimulated hypertrophy (13) in vascular smooth muscle cells. These actions may thus sensitize cardiac responses to circulating or locally produced Ang II. The cardiac extracellular matrix is also a potential steroid target. Indeed, both corticosterone (49) and aldosterone (21, 22) induce cardiac fibrosis via an indirect unexplained mechanism (50).

In conclusion, we provide the first evidence for the existence of a cardiac endocrine system producing aldosterone and corticosterone in the rat. However, the synthesis of results using different complementary approaches will be necessary to define the functional effects and the overall physiological relevance of this system.

	ACKNOWLEDGEMENTS

We thank Dr. L. Rappaport and Dr. A. Carayon for helpful discussions and Dr. B. Prendergast for kind help in preparing the manuscript. We also thank T. Dakhli for animal handling.

	FOOTNOTES

^* This study was supported by grants from INSERM.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Recipient of a fellowship from the Ministère de la Recherche et de l'Enseignement Supérieur.

^§ Present address: Service de Biochimie, CHU Pitié-Salpétrière, 75634, Paris Cedex 13, France.

^¶ To whom correspondence should be addressed: U127-INSERM, Hôpital Lariboisière, 41 Bd de la Chapelle, 75475 Paris Cedex 10, France. Tel.: 33-0142858065; Fax: 33-0148742315; E-mail: claude.delcayre{at}inserm.lrb.ap-hop-paris.fr.

¹ The abbreviations used are: OHase, hydroxylase; DOC, 11-deoxycorticosterone; ACTH, adrenocorticotropic hormone; Aldo, aldosterone; Ang, angiotensin; RT, reverse transcriptase; PCR, polymerase chain reaction; bp, base pair(s).

	REFERENCES

Top Abstract Introduction Procedures Results Discussion References

1. Nomura, M., Morohashi, K. I., Kirita, S., Nonaka, Y., Okamoto, M., Nawata, H., and Omura, T. (1993) J. Biochem. (Tokyo) 113, 144-152[Abstract/Free Full Text]
2. Fardella, C. E., and Miller, W. L. (1996) Annu. Rev. Nutr. 16, 443-470[CrossRef][Medline] [Order article via Infotrieve]
3. Tremblay, A., Waterman, M. R., Parker, K. L., Lehoux, J. G. (1991) J. Biol. Chem. 266, 2245-2251[Abstract/Free Full Text]
4. Shibata, H., Ogishima, T., Mitani, F., Suzuki, H., Murukami, M., Saruta, T., and Ishimura, Y. (1991) Endocrinology 128, 2534-2539[Abstract/Free Full Text]
5. Biglieri, E. G., Arteaga, E., and Kater, C. E. (1987) Ann. N. Y. Acad. Sci. 512, 426-437[CrossRef][Medline] [Order article via Infotrieve]
6. Aguilera, G., Fujita, K., and Catt, K. J. (1981) Endocrinology 108, 522-528[Abstract/Free Full Text]
7. Mukai, K., Imai, M., Shimada, H., and Ishimura, Y. (1993) J. Biol. Chem. 268, 9130-9137[Abstract/Free Full Text]
8. Mellon, S. H., Bair, S. R., and Monis, H. (1995) J. Biol. Chem. 270, 1643-1649[Abstract/Free Full Text]
9. Casey, M. L., and MacDonald, P. C. (1982) Endocr. Rev. 3, 396-403[Abstract/Free Full Text]
10. Mellon, S. H., and Deschepper, C. F. (1993) Brain. Res. 629, 283-292[CrossRef][Medline] [Order article via Infotrieve]
11. Takeda, Y., Miyamori, I., Yoneda, T., Iki, K., Hatakeyama, H., Blair, I. A., Hsieh, F. Y., Takeda, R. (1996) Endocrinology 135, 2283-2286[Abstract]
12. Takeda, Y., Miyamori, I., Yoneda, T., Iki, K., Hatakeyama, H., Blair, I. A., Hsieh, F. Y., Takeda, R. (1995) Hypertension 25, 170-173[Abstract/Free Full Text]
13. Hatakeyama, H., Miyamori, I., Fujita, T., Takeda, Y., Takeda, R., and Yamamoto, H. (1994) J. Biol. Chem. 269, 24316-24320[Abstract/Free Full Text]
14. Knox, J. R., and Lockett, M. F. (1969) J. Endocrinol. 43, 315-316[Abstract/Free Full Text]
15. Zhao, H. F., Labrie, C., Simard, J., de Launoit, Y., Trudel, C., Martel, C., Rheaume, E., Dupont, E., Luu-The, V., Pelletier, G., Labrie, F. (1991) J. Biol. Chem. 266, 583-593[Abstract/Free Full Text]
16. Agarval, M. K., and Philippe, M. (1979) J. Mol. Cell. Cardiol. 11, 115-126[CrossRef][Medline] [Order article via Infotrieve]
17. Funder, J. W., Duval, D., and Meyer, P. (1973) Endocrinology 93, 1300-1308[Abstract/Free Full Text]
18. Lombes, M., Oblin, M. E., Gasc, J. M., Baulieu, E., Farman, N., Bonvalet, J. P. (1992) Circ. Res. 71, 503-510[Abstract/Free Full Text]
19. Funder, J. W., Pearce, P. T., Smith, R., and Smith, A. I. (1988) Science 242, 583-585[Abstract/Free Full Text]
20. Walker, B. R., Yau, J. L., and Brett, L. P. (1991) Endocrinology 129, 3305-3312[Abstract/Free Full Text]
21. Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S., Weber, K. T. (1990) Circ. Res. 67, 1355-1364[Abstract/Free Full Text]
22. Robert, V., Nguyen, V. T., Cheav, S. L., Mouas, C., Swynghedauw, B., Delcayre, C. (1994) Hypertension 24, 30-36[Abstract/Free Full Text]
23. Campbell, S. E., Janicki, J. S., Mastubara, B. B., Weber, K. T. (1993) Am. J. Hypertens. 6, 487-495[Medline] [Order article via Infotrieve]
24. Ikeda, U., Hyman, R., Smith, T. W., Medford, R. M. (1991) J. Biol. Chem. 266, 12058-12066[Abstract/Free Full Text]
25. Lindpaintner, K., Manwen, J., Nierdermaier, N., Wilhelm, M. J., Ganten, D. (1990) Circ. Res. 67, 564-573[Abstract/Free Full Text]
26. Della Bruna, R., Ries, S., Himmelstoss, C., and Kurtz, A. (1995) J. Hypertens. 13, 763-769[Medline] [Order article via Infotrieve]
27. Delcayre, C., Klug, D., Nguyen, V. T., Mouas, C., Swynghedauw, B. (1992) Am. J. Physiol. 263, H1537-H1545[Abstract/Free Full Text]
28. Bradford, M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
29. Aupetit-Faisant, B., Battaglia, C., Zenatti, M., Emeric-Blanchouin, N., and Legrand, J. C. (1993) J. Clin. Endocrinol. Metab. 76, 38-43[Abstract]
30. Aupetit, B., Accarie, C., Emeric, N., Vonarx, V., and Legrand, J. C. (1983) Biochim. Biophys. Acta 752, 73-78[Medline] [Order article via Infotrieve]
31. Curnow, K. M., Tusie-Luna, M. T., Pascoe, L., Natarajan, R., Gu, J. L., Nadler, J. L., White, P. C. (1991) Mol. Endocrinol. 5, 1513-1522[Abstract/Free Full Text]
32. Tremblay, A., Parker, K. L., and Lehoux, J. G. (1992) Endocrinology 130, 3152-3158[Abstract/Free Full Text]
33. Heymes, C., Swynghedauw, B., and Chevalier, B. (1994) Circulation 90, 1328-1333[Abstract/Free Full Text]
34. Malee, M. P., and Mellon, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4731-4735[Abstract/Free Full Text]
35. Takeda, Y., Miyamori, I., Yoneda, T., Hatakeyama, H., Inaba, S., Furukawa, K., Mabuchi, H., and Takeda, R. (1996) J. Clin. Endocrinol. Metab. 81, 2797-2800[Abstract/Free Full Text]
36. Danser, A. H. J., Van Kats, J. P., Admiraal, P. J. J., Derkx, F. H. M., Lamers, J. M. J., Verdouw, P. D., Saxena, P. R., Schalekamp, M. A. D. H. (1994) Hypertension 24, 37-48[Abstract/Free Full Text]
37. Dell'Italia, L. J., Meng, Q. C., Balcells, E., Wei, C. C., Palmer, R., Hageman, G. R., Durand, J., Hankes, G. H., Oparil, S. (1997) J. Clin. Invest. 100, 253-258[Medline] [Order article via Infotrieve]
38. Huet, M., and Cantin, M. (1974) Lab. Invest. 30, 154-158
39. Dzau, V. J. (1988) Circulation 77, Suppl. I, 4-13
40. Huang, M. H., Friend, D. S., Sunday, M. E., Singh, K., Haley, K., Austen, K. F., Kelly, R. A., Smith, W. T. (1996) J. Clin. Invest. 98, 1298-1303[Medline] [Order article via Infotrieve]
41. Adler, G. K., Chen, R., Menachery, A. I., Braley, L. M., Williams, G. H. (1993) Endocrinology 133, 2235-2240[Abstract/Free Full Text]
42. Mukai, K., Imai, M., Shimada, H., Okada, Y., Ogishima, T., and Ishimura, Y. (1991) Biochem. Biophys. Res. Commun. 180, 1187-1193[CrossRef][Medline] [Order article via Infotrieve]
43. Clyne, C. D., White, P. C., and Rainey, W. E. (1996) Endocr. Res. 22, 485-492[Medline] [Order article via Infotrieve]
44. Holland, O. B., and Carr, B. (1993) Endocrinology 132, 2666-2673[Abstract/Free Full Text]
45. Wehling, M., Neylon, C. B., Fullerton, M., Bobik, A., and Funder, J. W. (1995) Circ. Res. 76, 673-679
46. Hayashi, T., Nakai, T., and Miyabo, S. (1991) Am. J. Physiol. 261, C106-C114[Abstract/Free Full Text]
47. Korichneva, I., Puceat, M., Millanvoye-Van Brussel, E., Geraud, G., Vassort, G. (1995) J. Mol. Cell. Cardiol. 27, 2521-2528[CrossRef][Medline] [Order article via Infotrieve]
48. Ullian, M. E., Schelling, J. R., and Limas, S. T. (1992) Hypertension 20, 67-73[Abstract/Free Full Text]
49. Young, M., Fullerton, M., Dilley, R., and Funder, J. (1994) J. Clin. Invest. 93, 2578-2583
50. Robert, V., Silvestre, J. S., Charlemagne, D., Sabri, A., Trouve, P., Wassef, M., Swynghedauw, B., and Delcayre, C. (1995) Hypertension 26, 971-978[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				A. Jadhav and J. F. Ndisang Heme Arginate Suppresses Cardiac Lesions and Hypertrophy in Deoxycorticosterone Acetate-Salt Hypertension Experimental Biology and Medicine, July 1, 2009; 234(7): 764 - 778. [Abstract] [Full Text] [PDF]

				D. S. De Silva, R. M. Wilson, C. Hutchinson, P. C. Ip, A. G. Garcia, S. Lancel, M. Ito, D. R. Pimentel, and F. Sam Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1983 - H1993. [Abstract] [Full Text] [PDF]

				S. Klotz, D. Burkhoff, I. M. Garrelds, F. Boomsma, and A.H.J. Danser The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur. Heart J., April 1, 2009; 30(7): 805 - 812. [Abstract] [Full Text] [PDF]

				S. D. Navaneethan, S. U. Nigwekar, A. R. Sehgal, and G. F.M. Strippoli Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 542 - 551. [Abstract] [Full Text] [PDF]

				J. L. Wilkinson-Berka, G. Tan, K. Jaworski, and A. G. Miller Identification of a Retinal Aldosterone System and the Protective Effects of Mineralocorticoid Receptor Antagonism on Retinal Vascular Pathology Circ. Res., January 2, 2009; 104(1): 124 - 133. [Abstract] [Full Text] [PDF]

				A. Jadhav, E. Torlakovic, and J. F. Ndisang Interaction Among Heme Oxygenase, Nuclear Factor-{kappa}B, and Transcription Activating Factors in Cardiac Hypertrophy in Hypertension Hypertension, November 1, 2008; 52(5): 910 - 917. [Abstract] [Full Text] [PDF]

				A. Karagiannis, K. Tziomalos, A. I Kakafika, V. G Athyros, F. Harsoulis, and D. P Mikhailidis Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas Endocr. Relat. Cancer, September 1, 2008; 15(3): 693 - 700. [Abstract] [Full Text] [PDF]

				L. Michea, A. Villagran, A. Urzua, S. Kuntsmann, P. Venegas, L. Carrasco, M. Gonzalez, and E. T. Marusic Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats Hypertension, August 1, 2008; 52(2): 295 - 300. [Abstract] [Full Text] [PDF]

				J. T. Mathew, H. Patni, A. N. Chaudhary, W. Liang, A. Gupta, P. N. Chander, G. Ding, and P. C. Singhal Aldosterone induces mesangial cell apoptosis both in vivo and in vitro Am J Physiol Renal Physiol, July 1, 2008; 295(1): F73 - F81. [Abstract] [Full Text] [PDF]

				H. M. Siragy and C. Xue Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats Exp Physiol, July 1, 2008; 93(7): 817 - 824. [Abstract] [Full Text] [PDF]

				T. Muto, N. Ueda, T. Opthof, T. Ohkusa, K. Nagata, S. Suzuki, Y. Tsuji, M. Horiba, J.-K. Lee, H. Honjo, et al. Aldosterone modulates If current through gene expression in cultured neonatal rat ventricular myocytes Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2710 - H2718. [Abstract] [Full Text] [PDF]

				R. M. Ortiz, M. L. Graciano, J. J. Mullins, and K. D. Mitchell Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1584 - F1591. [Abstract] [Full Text] [PDF]

				H. Patni, J. T. Mathew, L. Luan, N. Franki, P. N. Chander, and P. C. Singhal Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1065 - F1071. [Abstract] [Full Text] [PDF]

				T. Ohtani, M. Ohta, K. Yamamoto, T. Mano, Y. Sakata, M. Nishio, Y. Takeda, J. Yoshida, T. Miwa, M. Okamoto, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R946 - R954. [Abstract] [Full Text] [PDF]

				Wenxia Chai, Y. M Hoedemaekers, R. H. van Schaik, M. van Fessem, I. M Garrelds, J. J Saris, D. Dooijes, F. J ten Cate, M. M. Kofflard, and A. J. Danser Cardiac aldosterone in subjects with hypertrophic cardiomyopathy Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 225 - 230. [Abstract] [PDF]

				M. P. Ponda and T. H. Hostetter Aldosterone Antagonism in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 668 - 677. [Full Text] [PDF]

				S. Johar, A. C. Cave, A. Narayanapanicker, D. J. Grieve, and A. M. Shah Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase FASEB J, July 1, 2006; 20(9): 1546 - 1548. [Abstract] [Full Text] [PDF]

				C. Boixel, B. Gavillet, J.-S. Rougier, and H. Abriel Aldosterone increases voltage-gated sodium current in ventricular myocytes Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2257 - H2266. [Abstract] [Full Text] [PDF]

				L. Hunyady and K. J. Catt Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970. [Abstract] [Full Text] [PDF]

				W. Chai, I. M. Garrelds, R. de Vries, and A.H. Jan Danser Cardioprotective Effects of Eplerenone in the Rat Heart: Interaction With Locally Synthesized or Blood-Derived Aldosterone? Hypertension, April 1, 2006; 47(4): 665 - 670. [Abstract] [Full Text] [PDF]

				N. C Shah, S. Pringle, and A. Struthers Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 20 - 30. [Abstract] [PDF]

				J. Nehme, N. Mercier, C. Labat, A. Benetos, M. E Safar, C. Delcayre, and P. Lacolley Differences Between Cardiac and Arterial Fibrosis and Stiffness in Aldosterone-Salt Rats: Effect of Eplerenone Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 31 - 39. [Abstract] [PDF]

				M. Yamamuro, M. Yoshimura, M. Nakayama, K. Abe, M. Shono, S. Suzuki, T. Sakamoto, Y. Saito, K. Nakao, H. Yasue, et al. Direct Effects of Aldosterone on Cardiomyocytes in the Presence of Normal and Elevated Extracellular Sodium Endocrinology, March 1, 2006; 147(3): 1314 - 1321. [Abstract] [Full Text] [PDF]

				T. R. Marcy and T. L. Ripley Aldosterone antagonists in the treatment of heart failure Am. J. Health Syst. Pharm., January 1, 2006; 63(1): 49 - 58. [Abstract] [Full Text] [PDF]

				P. Ye, C. J. Kenyon, S. M. MacKenzie, A. S. Jong, C. Miller, G. A. Gray, A. Wallace, A. S. Ryding, J. J. Mullins, M. W. McBride, et al. The Aldosterone Synthase (CYP11B2) and 11{beta}-Hydroxylase (CYP11B1) Genes Are Not Expressed in the Rat Heart Endocrinology, December 1, 2005; 146(12): 5287 - 5293. [Abstract] [Full Text] [PDF]

				W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, and G. S. Francis Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure Mayo Clin. Proc., December 1, 2005; 80(12): 1623 - 1630. [Abstract] [PDF]

				J. C. Aldigier, T. Kanjanbuch, L.-J. Ma, N. J. Brown, and A. B. Fogo Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3306 - 3314. [Abstract] [Full Text] [PDF]

				T. Karram, A. Abbasi, S. Keidar, E. Golomb, I. Hochberg, J. Winaver, A. Hoffman, and Z. Abassi Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1351 - H1358. [Abstract] [Full Text] [PDF]

				T. Sugiyama, T. Yoshimoto, K. Tsuchiya, N. Gochou, Y. Hirono, T. Tateno, N. Fukai, M. Shichiri, and Y. Hirata Aldosterone Induces Angiotensin Converting Enzyme Gene Expression via a JAK2-Dependent Pathway in Rat Endothelial Cells Endocrinology, September 1, 2005; 146(9): 3900 - 3906. [Abstract] [Full Text] [PDF]

				M. K. Rude, T.-A. S. Duhaney, G. M. Kuster, S. Judge, J. Heo, W. S. Colucci, D. A. Siwik, and F. Sam Aldosterone Stimulates Matrix Metalloproteinases and Reactive Oxygen Species in Adult Rat Ventricular Cardiomyocytes Hypertension, September 1, 2005; 46(3): 555 - 561. [Abstract] [Full Text] [PDF]

				J. M C Connell and E. Davies The new biology of aldosterone J. Endocrinol., July 1, 2005; 186(1): 1 - 20. [Abstract] [Full Text] [PDF]

				A. Fiebeler, J. Nussberger, E. Shagdarsuren, S. Rong, G. Hilfenhaus, N. Al-Saadi, R. Dechend, M. Wellner, S. Meiners, C. Maser-Gluth, et al. Aldosterone Synthase Inhibitor Ameliorates Angiotensin II-Induced Organ Damage Circulation, June 14, 2005; 111(23): 3087 - 3094. [Abstract] [Full Text] [PDF]

				J. Katada, T. Meguro, H. Saito, A. Ohashi, T. Anzai, S. Ogawa, and T. Yoshikawa Persistent Cardiac Aldosterone Synthesis in Angiotensin II Type 1A Receptor-Knockout Mice After Myocardial Infarction Circulation, May 3, 2005; 111(17): 2157 - 2164. [Abstract] [Full Text] [PDF]

				B. J Barnes and P. A Howard Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure Ann. Pharmacother., January 1, 2005; 39(1): 68 - 76. [Abstract] [Full Text] [PDF]

				J. W. Funder Cardiac Synthesis of Aldosterone: Going, Going, Gone... ? Endocrinology, November 1, 2004; 145(11): 4793 - 4795. [Full Text] [PDF]

				E. P. Gomez-Sanchez, N. Ahmad, D. G. Romero, and C. E. Gomez-Sanchez Origin of Aldosterone in the Rat Heart Endocrinology, November 1, 2004; 145(11): 4796 - 4802. [Abstract] [Full Text] [PDF]

				A. D Struthers Aldosterone blockade in cardiovascular disease Heart, October 1, 2004; 90(10): 1229 - 1234. [Full Text] [PDF]

				S. Nakamura, M. Yoshimura, M. Nakayama, T. Ito, Y. Mizuno, E. Harada, T. Sakamoto, Y. Saito, K. Nakao, H. Yasue, et al. Possible Association of Heart Failure Status With Synthetic Balance Between Aldosterone and Dehydroepiandrosterone in Human Heart Circulation, September 28, 2004; 110(13): 1787 - 1793. [Abstract] [Full Text] [PDF]

				A. Garnier, J. K. Bendall, S. Fuchs, B. Escoubet, F. Rochais, J. Hoerter, J. Nehme, M.-L. Ambroisine, N. De Angelis, G. Morineau, et al. Cardiac Specific Increase in Aldosterone Production Induces Coronary Dysfunction in Aldosterone Synthase-Transgenic Mice Circulation, September 28, 2004; 110(13): 1819 - 1825. [Abstract] [Full Text] [PDF]

				F. Xiao, J. R. Puddefoot, S. Barker, and G. P. Vinson Mechanism for Aldosterone Potentiation of Angiotensin II-Stimulated Rat Arterial Smooth Muscle Cell Proliferation Hypertension, September 1, 2004; 44(3): 340 - 345. [Abstract] [Full Text] [PDF]

				N. Ahmad, D. G. Romero, E. P. Gomez-Sanchez, and C. E. Gomez-Sanchez Do Human Vascular Endothelial Cells Produce Aldosterone? Endocrinology, August 1, 2004; 145(8): 3626 - 3629. [Abstract] [Full Text] [PDF]

				A. Mano, T. Tatsumi, J. Shiraishi, N. Keira, T. Nomura, M. Takeda, S. Nishikawa, S. Yamanaka, S. Matoba, M. Kobara, et al. Aldosterone Directly Induces Myocyte Apoptosis Through Calcineurin-Dependent Pathways Circulation, July 20, 2004; 110(3): 317 - 323. [Abstract] [Full Text] [PDF]

				R. Bos, N. Mougenot, O. Mediani, P. M. Vanhoutte, and P. Lechat Potassium Canrenoate, an Aldosterone Receptor Antagonist, Reduces Isoprenaline-Induced Cardiac Fibrosis in the Rat J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1160 - 1166. [Abstract] [Full Text] [PDF]

				Q. Wang, S. Clement, G. Gabbiani, J.-D. Horisberger, M. Burnier, B. C. Rossier, and E. Hummler Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet Am J Physiol Renal Physiol, June 1, 2004; 286(6): F1178 - F1184. [Abstract] [Full Text] [PDF]

				H. Oberleithner, T. Ludwig, C. Riethmuller, U. Hillebrand, L. Albermann, C. Schafer, V. Shahin, and H. Schillers Human Endothelium: Target for Aldosterone Hypertension, May 1, 2004; 43(5): 952 - 956. [Abstract] [Full Text] [PDF]

				H. Oberleithner Unorthodox Sites and Modes of Aldosterone Action Physiology, April 1, 2004; 19(2): 51 - 54. [Abstract] [Full Text] [PDF]

				N. Tsybouleva, L. Zhang, S. Chen, R. Patel, S. Lutucuta, S. Nemoto, G. DeFreitas, M. Entman, B. A. Carabello, R. Roberts, et al. Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy Circulation, March 16, 2004; 109(10): 1284 - 1291. [Abstract] [Full Text] [PDF]

				F. K Shieh, E. Kotlyar, and F. Sam Aldosterone and cardiovascular remodelling: focus on myocardial failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 3 - 13. [Abstract] [PDF]

				A. D Struthers and T. M MacDonald Review of aldosterone- and angiotensin II-induced target organ damage and prevention Cardiovasc Res, March 1, 2004; 61(4): 663 - 670. [Abstract] [Full Text] [PDF]

				K. T Weber, Yao Sun, L. A Wodi, A. Munir, E. Jahangir, R. A Ahokas, I. C Gerling, A. E Postlethwaite, and K. J Warrington Toward a broader understanding of aldosterone in congestive heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 155 - 163. [Abstract] [PDF]

				B. Pitt, C. T Stier Jr, and S. Rajagopalan Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 164 - 168. [Abstract] [PDF]

				T. H. Hostetter and H. N. Ibrahim Aldosterone in Chronic Kidney and Cardiac Disease J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2395 - 2401. [Abstract] [Full Text] [PDF]

				B. M.W. Schmidt, S. Oehmer, C. Delles, R. Bratke, M. P. Schneider, A. Klingbeil, E. H. Fleischmann, and R. E. Schmieder Rapid Nongenomic Effects of Aldosterone on Human Forearm Vasculature Hypertension, August 1, 2003; 42(2): 156 - 160. [Abstract] [Full Text] [PDF]

				R. M. LOSEL, E. FALKENSTEIN, M. FEURING, A. SCHULTZ, H.-C. TILLMANN, K. ROSSOL-HASEROTH, and M. WEHLING Nongenomic Steroid Action: Controversies, Questions, and Answers Physiol Rev, July 1, 2003; 83(3): 965 - 1016. [Abstract] [Full Text] [PDF]

				J. S. Williams and G. H. Williams 50th Anniversary of Aldosterone J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2364 - 2372. [Full Text] [PDF]

				P. C. White Aldosterone: Direct Effects on and Production by the Heart J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2376 - 2383. [Full Text] [PDF]

				A. Cittadini, M. G. Monti, J. Isgaard, C. Casaburi, H. Stromer, A. Di Gianni, R. Serpico, L. Saldamarco, M. Vanasia, and L. Sacca Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure Cardiovasc Res, June 1, 2003; 58(3): 555 - 564. [Abstract] [Full Text] [PDF]

				N. J. Brown Eplerenone: Cardiovascular Protection Circulation, May 20, 2003; 107(19): 2512 - 2518. [Abstract] [Full Text] [PDF]

				A. J. Casal, J.-S. Silvestre, C. Delcayre, and A. M. Capponi Expression and Modulation of Steroidogenic Acute Regulatory Protein Messenger Ribonucleic Acid in Rat Cardiocytes and after Myocardial Infarction Endocrinology, May 1, 2003; 144(5): 1861 - 1868. [Abstract] [Full Text] [PDF]

				C. Wang, J. Chao, and L. Chao Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R1031 - R1036. [Abstract] [Full Text] [PDF]

				T. Ito, M. Yoshimura, S. Nakamura, M. Nakayama, Y. Shimasaki, E. Harada, Y. Mizuno, M. Yamamuro, M. Harada, Y. Saito, et al. Inhibitory Effect of Natriuretic Peptides on Aldosterone Synthase Gene Expression in Cultured Neonatal Rat Cardiocytes Circulation, February 18, 2003; 107(6): 807 - 810. [Abstract] [Full Text] [PDF]

				M. F. Rousseau, O. Gurne, D. Duprez, W. Van Mieghem, A. Robert, S. Ahn, L. Galanti, J.-M. Ketelslegers, and Belgian RALES Investigators Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1596 - 1601. [Abstract] [Full Text] [PDF]

				J. C. Barbato, P. J. Mulrow, J. I. Shapiro, and R. Franco-Saenz Rapid Effects of Aldosterone and Spironolactone in the Isolated Working Rat Heart Hypertension, August 1, 2002; 40(2): 130 - 135. [Abstract] [Full Text] [PDF]

				A. D. Tiago, D. Badenhorst, D. Skudicky, A. J. Woodiwiss, G. P. Candy, R. Brooksbank, K. Sliwa, P. Sareli, and G. R. Norton An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy Cardiovasc Res, June 1, 2002; 54(3): 584 - 589. [Abstract] [Full Text] [PDF]

				S. Neumann, K. Huse, R. Semrau, A. Diegeler, R. Gebhardt, G. H. Buniatian, and G. H. Scholz Aldosterone and D-Glucose Stimulate the Proliferation of Human Cardiac Myofibroblasts In Vitro Hypertension, March 1, 2002; 39(3): 756 - 760. [Abstract] [Full Text] [PDF]

				K. E. Sheppard and D. J. Autelitano 11{beta}-Hydroxysteroid Dehydrogenase 1 Transforms 11-Dehydrocorticosterone into Transcriptionally Active Glucocorticoid in Neonatal Rat Heart Endocrinology, January 1, 2002; 143(1): 198 - 204. [Abstract] [Full Text] [PDF]

				K. T. Weber Aldosterone in Congestive Heart Failure N. Engl. J. Med., December 6, 2001; 345(23): 1689 - 1697. [Full Text] [PDF]

				C. Ngarmukos and R. J. Grekin Nontraditional aspects of aldosterone physiology Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1122 - E1127. [Abstract] [Full Text] [PDF]

				J. P. van Kats, D. Methot, P. Paradis, D. W. Silversides, and T. L. Reudelhuber Use of a Biological Peptide Pump to Study Chronic Peptide Hormone Action in Transgenic Mice. DIRECT AND INDIRECT EFFECTS OF ANGIOTENSIN II ON THE HEART J. Biol. Chem., November 16, 2001; 276(47): 44012 - 44017. [Abstract] [Full Text] [PDF]

				J.-P. Benitah, E. Perrier, A. M. Gomez, and G. Vassort Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes J. Physiol., November 15, 2001; 537(1): 151 - 160. [Abstract] [Full Text] [PDF]

				C. E. Gomez-Sanchez and E. P. Gomez-Sanchez Cardiac Steroidogenesis--New Sites of Synthesis, or Much Ado About Nothing? J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5118 - 5120. [Full Text] [PDF]

				M. J. Young, C. D. Clyne, T. J. Cole, and J. W. Funder Cardiac Steroidogenesis in the Normal and Failing Heart J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5121 - 5126. [Abstract] [Full Text] [PDF]

				D. Le Menuet, R. Isnard, M. Bichara, S. Viengchareun, M. Muffat-Joly, F. Walker, M.-C. Zennaro, and M. Lombes Alteration of Cardiac and Renal Functions in Transgenic Mice Overexpressing Human Mineralocorticoid Receptor J. Biol. Chem., October 12, 2001; 276(42): 38911 - 38920. [Abstract] [Full Text] [PDF]

				E. Harada, M. Yoshimura, H. Yasue, O. Nakagawa, M. Nakagawa, M. Harada, Y. Mizuno, M. Nakayama, Y. Shimasaki, T. Ito, et al. Aldosterone Induces Angiotensin-Converting-Enzyme Gene Expression in Cultured Neonatal Rat Cardiocytes Circulation, July 10, 2001; 104(2): 137 - 139. [Abstract] [Full Text] [PDF]

				B. M. W. Schmidt, A. C. Georgens, N. Martin, H.-C. Tillmann, M. Feuring, M. Christ, and M. Wehling Interaction of Rapid Nongenomic Cardiovascular Aldosterone Effects with the Adrenergic System J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 761 - 767. [Abstract] [Full Text]

				A. Fiebeler, F. Schmidt, D. N. Muller, J.-K. Park, R. Dechend, M. Bieringer, E. Shagdarsuren, V. Breu, H. Haller, and F. C. Luft Mineralocorticoid Receptor Affects AP-1 and Nuclear Factor-{{kappa}}B Activation in Angiotensin II-Induced Cardiac Injury Hypertension, February 1, 2001; 37(2): 787 - 793. [Abstract] [Full Text] [PDF]

				Y. Mizuno, M. Yoshimura, H. Yasue, T. Sakamoto, H. Ogawa, K. Kugiyama, E. Harada, M. Nakayama, S. Nakamura, T. Ito, et al. Aldosterone Production Is Activated in Failing Ventricle in Humans Circulation, January 2, 2001; 103(1): 72 - 77. [Abstract] [Full Text] [PDF]

				J. Bauersachs, D. Fraccarollo, G. Ertl, N. Gretz, M. Wehling, and M. Christ Striking Increase of Natriuresis by Low-Dose Spironolactone in Congestive Heart Failure Only in Combination With ACE Inhibition : Mechanistic Evidence to Support RALES Circulation, November 7, 2000; 102(19): 2325 - 2328. [Abstract] [Full Text] [PDF]

				Y. Takeda, T. Yoneda, M. Demura, I. Miyamori, and H. Mabuchi Cardiac Aldosterone Production in Genetically Hypertensive Rats Hypertension, October 1, 2000; 36(4): 495 - 500. [Abstract] [Full Text] [PDF]

				T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure J. Am. Coll. Cardiol., September 1, 2000; 36(3): 838 - 844. [Abstract] [Full Text] [PDF]

				K. M. Kayes-Wandover and P. C. White Steroidogenic Enzyme Gene Expression in the Human Heart J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2519 - 2525. [Abstract] [Full Text]

				M. O. Boluyt and O. H.L. Bing Matrix gene expression and decompensated heart failure: The aged SHR model Cardiovasc Res, May 1, 2000; 46(2): 239 - 249. [Abstract] [Full Text] [PDF]

				J.-P. Benitah and G. Vassort Aldosterone Upregulates Ca2+ Current in Adult Rat Cardiomyocytes Circ. Res., December 3, 1999; 85(12): 1139 - 1145. [Abstract] [Full Text] [PDF]

				A. Hautanen, P. Toivanen, M. Manttari, L. Tenkanen, M. Kupari, V. Manninen, K. M. Kayes, S. Rosenfeld, and P. C. White Joint Effects of an Aldosterone Synthase (CYP11B2) Gene Polymorphism and Classic Risk Factors on Risk of Myocardial Infarction Circulation, November 30, 1999; 100(22): 2213 - 2218. [Abstract] [Full Text] [PDF]

				B. M. W. Schmidt, A. Montealegre, C. P. Janson, N. Martin, C. Stein-Kemmesies, A. Scherhag, M. Feuring, M. Christ, and M. Wehling Short Term Cardiovascular Effects of Aldosterone in Healthy Male Volunteers J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3528 - 3533. [Abstract] [Full Text] [PDF]

				K. T. Weber Aldosterone and Spironolactone in Heart Failure N. Engl. J. Med., September 2, 1999; 341(10): 752 - 755. [Full Text]

				K. C Wollert and H. Drexler The renin-angiotensin system and experimental heart failure Cardiovasc Res, September 1, 1999; 43(4): 838 - 849. [Abstract] [Full Text] [PDF]

				C. Delcayre and J.-S. Silvestre Aldosterone and the heart: towards a physiological function? Cardiovasc Res, July 1, 1999; 43(1): 7 - 12. [Full Text] [PDF]

				J.-S. Silvestre, C. Heymes, A. Oubenaissa, V. Robert, B. Aupetit-Faisant, A. Carayon, B. Swynghedauw, and C. Delcayre Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction : Effect of Angiotensin II Receptor Blockade and Role in Cardiac Fibrosis Circulation, May 25, 1999; 99(20): 2694 - 2701. [Abstract] [Full Text] [PDF]

				A. G. Mensah-Nyagan, J.-L. Do-Rego, D. Beaujean, V. Luu-The, G. Pelletier, and H. Vaudry Neurosteroids: Expression of Steroidogenic Enzymes and Regulation of Steroid Biosynthesis in the Central Nervous System Pharmacol. Rev., March 1, 1999; 51(1): 63 - 82. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silvestre, J.-S. Articles by Delcayre, C. Search for Related Content PubMed PubMed Citation Articles by Silvestre, J.-S. Articles by Delcayre, C. Social Bookmarking                      What's this?